Show simple item record

dc.contributor.authorJimenez-Fonseca, P.
dc.contributor.authorCarmona-Bayonas, A.
dc.contributor.authorLamarca, Angela
dc.contributor.authorBarriuso, Jorge
dc.contributor.authorCastano, A.
dc.contributor.authorBenavent, M.
dc.contributor.authorAlonso, V.
dc.contributor.authorRiesco, M. D.
dc.contributor.authorAlonso-Gordoa, T.
dc.contributor.authorCustodio, A.
dc.contributor.authorCanovas, M. S.
dc.contributor.authorHernando, J.
dc.contributor.authorLopez, C.
dc.contributor.authorLa Casta, A.
dc.contributor.authorMontes, A. F.
dc.contributor.authorMarazuela, M.
dc.contributor.authorCrespo, G.
dc.contributor.authorDiaz, J. A.
dc.contributor.authorFeliciangeli, E.
dc.contributor.authorGallego, J.
dc.contributor.authorLlanos, M.
dc.contributor.authorSegura, A.
dc.contributor.authorVilardell, F.
dc.contributor.authorPercovich, J. C.
dc.contributor.authorGrande, E.
dc.contributor.authorCapdevila, J.
dc.contributor.authorValle, Juan W
dc.contributor.authorGarcia-Carbonero, R.
dc.date.accessioned2021-10-28T09:26:10Z
dc.date.available2021-10-28T09:26:10Z
dc.date.issued2021en
dc.identifier.citationJimenez-Fonseca P, Carmona-Bayonas A, Lamarca A, Barriuso J, Casta�o A, Benavent M, et al. External validity of somatostatin analogues trials in advanced neuroendocrine neoplasms: the GETNE-TRASGU study. Neuroendocrinology. S. Karger AG; 2021.en
dc.identifier.pmid33508849en
dc.identifier.doi10.1159/000514808en
dc.identifier.urihttp://hdl.handle.net/10541/624698
dc.description.abstractIntroduction: Somatostatin analogues (SSA) prolong progression-free survival (PFS) in patients with well-differentiated gastroenteropancreatic neuroendocrine tumors (GEP-NETs). However, the eligibility criteria in randomized clinical trials (RCTs) have been restricted, which contrasts with the vast heterogeneity found in NETs. Methods: We identified patients with well-differentiated (Ki67% ?20%), metastatic GEP-NETs treated in first-line with SSA monotherapy from the Spanish R-GETNE registry. The therapeutic effect was evaluated using a Bayesian Cox model. The objective was to compare survival-based outcomes from real world clinical practice versus RCTs. Results: The dataset contained 535 patients with a median age of 62 years (range: 26-89). The median Ki67% was 4 (range: 0-20). The most common primary tumor sites were: midgut, 46%; pancreas, 34%; unknown primary, 10%; and colorectal, 10%. Half of the patients received octreotide LAR (n=266) and half, lanreotide autogel (n=269). The median PFS was 28.0 months (95% CI, 22.1-32.0) for octreotide vs 30.1 months (95% CI, 23.1-38.0) for lanreotide. The overall hazard ratio for lanreotide vs octreotide was 0.90 (95% credible interval, 0.71-1.12). The probability of effect sizes >30% with lanreotide vs octreotide was 2% and 6% for midgut and foregut NENs, respectively. Conclusion: Our study evaluated the external validity of RCTs examining SSAs in the real world, as well as the main effect-modifying factors (progression status, symptoms, tumor site, specific metastases, and analytical data).. Our results indicate that both octreotide LAR and lanreotide autogel had a similar effect on PFS. Consequently, both represent valid alternatives in patients with well-differentiated, metastatic GEP-NENs.en
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1159/000514808en
dc.titleExternal validity of somatostatin analogs trials in advanced neuroendocrine neoplasms: The GETNE-TRASGU studyen
dc.typeArticleen
dc.contributor.departmentMedical Oncology Department, Hospital Universitario Central de Asturias, ISPA, Oviedo, Spainen
dc.identifier.journalNeuroendocrinologyen
dc.description.noteen]


This item appears in the following Collection(s)

Show simple item record